The present invention is a device for holding an ophthalmic bottle of drops and instilling them in a patient's eye. The device rests on the boney lower orbital ridge for stability and correct delivery.

The dropper mount assembly includes an angled mirror and a clip that mounts to an eye drop bottle. The angled mirror allows the user to gain proper alignment by viewing a reflection of the expected trajectory of the medicinal eye drop to the eye of the user. The clip is configured to receive eye drop bottles having a circular or oval cross section and is capable of either being mounted from an axis end of the eye drop bottle or from a side of the eye drop bottle. The clip has a set of prongs that provide a number of features, including providing spring tension against the eye dropper bottle, are permitted to receive eye dropper bottles of variable sizes, and serve as a grip and leverage that assists the user in squeezing the eye drop bottle when the user contracts the prongs together.

A dispenser for use with a squeezable eyedropper bottle containing medication is disclosed having a first arm defining a first pivot end, a first dispensing end, a first exterior surface and a first interior surface. The dispenser includes a retention feature positioned on the first arm to removably engage the squeezable eyedropper bottle. The dispenser includes a second arm defining a second pivot end, a second dispensing end, a second exterior surface and a second interior surface, the second pivot end coupled to the first pivot end of the first arm so that the first interior surface is movable relative to the second interior surface of the second arm, the second arm configured to squeeze the squeezable eyedropper bottle as the second interior surface is moved towards the first interior surface such that the medication is dispensed from the squeezable eyedropper bottle.

This invention relates to a Nanostructured Lipid Carrier (NLC) particle comprising a therapeutic agent encapsulated therein for ocular delivery of the therapeutic agent, wherein the Nanostructured Lipid Carrier comprises: (i) a solid outer shell comprising a solid lipid, and (ii) a liquid core comprising a liquid lipid; and wherein the core comprises the therapeutic agent. Compositions of the NLC particles, use of the NLC particles, methods of treatment or prevention of an eye disorder and an eye drop dispenser are also provided.

Disclosed herein are improved dispensing devices for facilitating application of eye drops that are ergonomic, promote improved patient adherence, and eliminate the need for extraneous gadgets or facilitating devices that may add additional expense to users. A dispensing device can include a container body for storing drops and a nozzle coupled to the body for dispensing the drops. The device can include one or more channels defined on a surface of the container body and configured to couple, or otherwise mount or abut, to an anatomical structure of a user (such as, for example, a user's nose bridge or eyebrow ridge). The device can also include one or more grip areas defined on the container body and configured to allow a user to generally hold the device and to apply force thereto to dispense drops from the device.

An ocular implant including a drug releasing element and having an inlet portion and a Schlemm's canal portion distal to the inlet portion, the inlet portion being disposed at a proximal end of the implant and sized and configured to be placed within an anterior chamber of a human eye, the Schlemm's canal portion being arranged and configured to be disposed within Schlemm's canal of the eye when the inlet portion is disposed in the anterior chamber.

A therapeutic device for extended release drug delivery including a refillable reservoir configured to receive a therapeutic agent and having an outlet for delivery of the therapeutic agent to a patient from the reservoir over an extended period. A porous structure is coupled near the outlet of the reservoir, the porous structure formed of sintered material. A barrier layer is coupled to the reservoir on or adjacent a surface of the porous structure such that the therapeutic agent passes through both the porous structure and the barrier layer upon delivery from the reservoir through the outlet. The porous structure is tuned to deliver the therapeutic agent at a diffusion rate and the barrier layer is adapted to block passage of particles having an average particle size within an average particle size range that is outside an average particle size range blocked by the porous structure. Related methods and systems are provided.

An eye treatment apparatus is described. The apparatus includes an annular body that has a hollow optical zone in its center. An inner perimeter of the annular body surrounds the optical zone. The inner perimeter has a diameter that corresponds to a diameter of the eye's cornea. An outer perimeter of the annular body has a diameter such that the annular body can extend to underneath the eye lid in an open eye position when the eye treatment apparatus is in operation. In this way, the apparatus can be worn on the eye, where the hollow optical zone substantially corresponds to the cornea and does not interfere with the field of vision. The annular body also includes a storage chamber that stores therapeutic liquid for an eye. An outlet is coupled with the storage chamber such that, in operation, the therapeutic liquid can be dispensed to the eye.

To provide a device and a method for strengthening a cornea or a sclera or suppressing a progression of a disease in a non-invasive manner, enabling treatment in daily life without treatment in a confined state at a medical institution for a fixed period of time and without ablation of the corneal epithelium as in conventional corneal crosslinking. The above-described problem is solved by a non-invasive cornea and sclera strengthening device that irradiates violet light toward an eye administered with an administration agent used to strengthen a corneal tissue or a scleral tissue, and is configured so that an irradiance of the violet light onto a surface of the eye is within a range of 0.1 to 1 mW/cm.sup.2, and a time of irradiation of the violet light onto the eye is within a range of one to five hours per day.

An ophthalmological analysis system, comprising: an air-puff generating device configured to apply an air-puff to a user's at least one eye; and at least one sensors board configured to detect and record deformation of a cornea of the user during the air-puff; wherein the detection is a three dimensional (3D) active stereo detection; the sensors board further configured to find two applanation points and hysteresis of the cornea and to calculate intraocular pressure in the user's at least one eye accordingly.